Mark G. Kris, MD, discusses treatment options for <em>MET</em>-mutant non–small cell lung cancer.
Mark G. Kris, MD, the William and Joy Ruane Chair in Thoracic Oncology in Memorial Sloan Kettering Cancer Center, discusses treatment options forMET-mutant nonsmall cell lung cancer (NSCLC).
Evidence shows that patients with high levels ofMETamplification can be treated with drugs that target the MET kinase. The occurrence ofMETis common in the smoking patient population. The Memorial Sloan Kettering Cancer Center, according to Kris, sees as manyMETmutations asALKalterations. Kris suggests performing next-generation sequencing on every patient with NSCLC upon diagnosis to findMETmutations among other biomarkers.
There are a few drugs available that are effective in treatingMET-mutant NSCLC. Currently, the standard of care is crizotinib (Xalkori), but preliminary research shows that other drugs, including capmatinib, savolitinib, and tepotinib, have better degrees of benefit and tolerability compared with crizotinib. Kris believes these drugs will eventually be approved by the FDA and become the new standards of care for patients withMET
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More